Aspirin/esomeprazole

Drug Profile

Aspirin/esomeprazole

Alternative Names: Axanum; D961S; Esomeprazole/aspirin

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator AstraZeneca
  • Class 2 pyridinylmethylsulfinylbenzimidazoles; Antiplatelets; Antipyretics; Antirheumatics; Antiulcers; Gastric antisecretories; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Salicylates; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors; Nitric oxide stimulants; Platelet aggregation inhibitors; Proton pump inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cardiovascular disorders; NSAID-induced ulcer

Most Recent Events

  • 31 Mar 2015 Launched for Cardiovascular disorders (Prevention) in Sweden and Estonia (PO) before March 2015
  • 31 Mar 2015 Launched for NSAID-induced ulcer (Prevention) in Sweden and Estonia (PO) before March 2015
  • 20 Jan 2015 Launched for Cardiovascular disorders (Prevention) in Austria (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top